Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/04/22
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development ProgramsBusiness Wire • 05/04/22
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual MeetingBusiness Wire • 04/28/22
Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/27/22
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4Business Wire • 04/20/22
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022Business Wire • 04/08/22
Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker StatusBenzinga • 03/31/22
Clovis Oncology to seek FDA approval for ovarian cancer drug as a maintenance therapyMarket Watch • 03/31/22
Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO TrialBusiness Wire • 03/31/22
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286Business Wire • 03/16/22